Article

Reshaping Cell Line Development and CMC Strategy for Fast Responses to Pandemic Outbreak

2020-11-27

Abstract excerpt

The global pandemic outbreak, SARS-COV-2, which causes COVID-19, has coerced numerous pharmaceutical companies to sprint for the vaccine and therapeutic biologics development. Most of the therapeutic biologics are common human IgG antibodies, which were identified by next-generation sequencing with the B cells from the convalescent patients in less than one-month post-infection. While the global public health emer...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4b1194f4-14a7-58b7-92a7-1420461e22fa
DOI: 10.22541/au.160647487.78215012/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Reshaping Cell Line Development and CMC Strategy for Fast Responses to Pandemic OutbreakDOI 10.22541/au.160647487.78215012/v1Read

Rapid cGMP Manufacturing of COVID-19 monoclonal antibody using stable CHO cell poolsSemantic proximity Read

Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144Semantic proximity Read

Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-CloningSemantic proximity Read

The Role of the Biomanufacturing Industry in Developing Diagnostics and mRNA Vaccines Against COVID-19Semantic proximity Read

Status and future developments for downstream processing of biological products Perspectives from the Recovery XIX yield roundtable discussionsSemantic proximity Read

Scalable Production of a <i>De Novo</i> SARS-CoV-2 Antiviral miniprotein in E <i>scherichia coli</i>Semantic proximity Read

The Role of the Biomanufacturing Industry in Developing Diagnostics and mRNA Vaccines Against COVID-19Semantic proximity Read

Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable poolSemantic proximity Read

Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivationsSemantic proximity Read

From single‐cell cloning to high‐yield influenza virus production – implementing advanced technologies in vaccine process developmentSemantic proximity Read

Lentivirus for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety PerspectiveSemantic proximity Read

Platforms, advances, and technical challenges in virus-like particles-based vaccinesSemantic proximity Read